Niagen Bioscience (NASDAQ:NAGE – Free Report) had its price target hoisted by Roth Capital from $10.00 to $23.00 in a research note published on Friday,Benzinga reports. They currently have a buy rating on the stock.
Separately, Canaccord Genuity Group assumed coverage on shares of Niagen Bioscience in a research report on Tuesday, May 27th. They issued a “buy” rating and a $13.00 target price on the stock.
Read Our Latest Stock Report on NAGE
Niagen Bioscience Stock Up 12.5%
Niagen Bioscience Company Profile
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Read More
- Five stocks we like better than Niagen Bioscience
- How to Invest in the FAANG Stocks
- A Large Oil Supply Draw Could Mean Upside in These 3 Energy Names
- How to Use Stock Screeners to Find Stocks
- 3 Stocks Getting Rare Double Upgrades From Analysts
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- This Banking Giant Just Got a $90 Price Target Upgrade
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
